⚠ Evidence warning: Clinical trials or other evidence do not support the claims that broccoli and sulforaphane reduce cancer risk in people. This page keeps it as a report of what people, websites or other media say.

Broccoli for Cancer Chemoprevention

Aflatoxin mould on maize, the toxin in the Qidong trials
Aflatoxin mould on maize, the toxin in the Qidong trials

Broccoli is the single most-studied dietary chemopreventive agent in modern oncology research. Paul Talalay's 1992 PNAS paper identifying sulforaphane as the major broccoli-derived inducer of cancer-protective phase II enzymes launched a 30-year research program that has now produced cohort epidemiology, animal models in nearly every solid-tumor type, and several modest but positive human randomized controlled trials (RCTs). The mechanism is multimodal: accelerated phase II conjugation of carcinogens (the original Nrf2-mediated story); direct histone deacetylase inhibition that re-activates tumor suppressor gene expression; cell cycle arrest at G2/M and pro-apoptotic effects on transformed cells; angiogenesis suppression; and modulation of cancer stem cell self-renewal. The Cipolla 2015 prostate cancer trial in biochemical-recurrence patients and reports of sulforaphane in osteosarcoma are presented as the human bridge between mechanism and clinical effect. Realistic framing matters: broccoli is best understood as a prevention strategy and an adjunct, not as a primary treatment for established cancer.


Table of Contents

  1. Talalay's 1992 Discovery
  2. The Qidong Aflatoxin Chemoprevention Trials
  3. HDAC Inhibition as a Second Mechanism
  4. Breast Cancer Evidence
  5. Prostate Cancer Evidence (Cipolla Randomized Controlled Trial)
  6. Bladder and Urothelial Cancer
  7. Colorectal Cancer
  8. Lung Cancer Chemoprevention
  9. Effects on Cancer Stem Cells
  10. What Broccoli Does Not Do
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Talalay's 1992 Discovery

The modern broccoli chemoprevention story begins in 1992 at the Johns Hopkins School of Medicine, where Paul Talalay and his postdoctoral fellow Yuesheng Zhang had spent years searching for the molecular agent responsible for the observed protective effect of cruciferous vegetables in carcinogen-induced rodent tumor models. The lab's screening approach was operationally elegant: extract a vegetable, fractionate the extract by chromatography, and assay each fraction for its ability to induce the phase II marker enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) in murine hepatoma cells in culture.

Broccoli extracts repeatedly produced the highest NQO1 induction of any tested vegetable. The active fraction was isolated, crystallized, and structurally characterized as sulforaphane — the isothiocyanate derived from the glucosinolate glucoraphanin. The 1992 PNAS paper (Zhang Y, Talalay P, Cho CG, Posner GH) reporting the isolation, structure, and chemopreventive activity of sulforaphane is one of the most highly cited papers in food chemoprevention research, with over 2,000 citations.

The Talalay laboratory subsequently demonstrated that sulforaphane prevented mammary tumor formation in DMBA (7,12-dimethylbenz[a]anthracene)-treated rats by approximately 50%, providing the first mammalian whole-animal in vivo demonstration that the dietary molecule could prevent chemically-induced cancer; the 1994 report (Zhang et al., PNAS) describes significantly reduced incidence, number and weight of mammary tumors, and delayed tumor development. The follow-up 1997 paper (Fahey JW, Zhang Y, Talalay P, PNAS) demonstrated that 3-day-old sprouts of certain crucifers including broccoli contained 10-100 times higher levels of glucoraphanin than the corresponding mature plants — redirecting much of the subsequent research toward sprouts as a more concentrated source.

Back to Table of Contents

The Qidong Aflatoxin Chemoprevention Trials

The most rigorous human chemoprevention evidence for broccoli comes from a series of trials conducted in Qidong, Jiangsu province, China — a region historically characterized by both very high aflatoxin contamination of dietary staples (corn and peanuts) and one of the highest age-adjusted hepatocellular carcinoma incidence rates in the world. The Qidong studies were led by Thomas Kensler at Johns Hopkins with Hopkins colleagues including Patricia Egner and John Groopman, in collaboration with Chinese investigators (Chen JG, Qian GS, Wang JB and others), over more than two decades.

The first major trial in this series (Kensler et al. 2005, Cancer Epidemiology Biomarkers & Prevention, PMID 16284385) randomized 200 healthy adults to a nightly broccoli sprout hot-water infusion containing either 400 micromol glucoraphanin or under 3 micromol (the placebo) for two weeks. Urinary aflatoxin-DNA adducts and aflatoxin-mercapturic acid metabolites were measured at multiple timepoints. The main comparison showed no effect: urinary aflatoxin-N7-guanine did not differ between the two arms (P = 0.68), and neither did the air-pollution marker phenanthrene tetraol (P = 0.29). The reason offered is that people differ greatly in how much sulforaphane they actually make from glucoraphanin, because gut bacteria do the conversion. So the result appeared only as a correlation inside the treated group: those who excreted more sulforaphane metabolites had lower aflatoxin-DNA adducts (P = 0.002; R = 0.31). A link to the glutathione S-transferase M1 (GSTM1) gene, with GSTM1-null subjects showing blunted but still measurable responses, is described in some accounts of this trial; the trial's abstract does not report one.

Subsequent Qidong trials extended the work to air pollutants, particularly benzene and acrolein. The Egner 2014 trial (Cancer Prevention Research, PMID 24913818) recruited 291 people from the rural He-He Township, in an area the authors describe as having substantial levels of airborne pollutants, and randomized them to 12 weeks of a broccoli sprout beverage providing 600 µmol glucoraphanin plus 40 µmol sulforaphane daily, or placebo. It demonstrated a 61% increase in urinary benzene-mercapturate and a 23% increase in acrolein-mercapturate excretion, sustained throughout the intervention; crotonaldehyde excretion did not change. Sulforaphane metabolites in urine showed that uptake did not decline over the 12 weeks.

These Qidong trials are widely considered the strongest human-subject evidence that a dietary intervention can measurably accelerate carcinogen elimination at clinically meaningful magnitudes. They do not prove cancer prevention in humans — that would require a multi-decade outcome trial that has not been done — but they bridge mechanism to a verifiable biochemical effect in real people.

Back to Table of Contents

HDAC Inhibition as a Second Mechanism

Beyond the Nrf2/phase II enzyme story that dominated the first decade of sulforaphane research, the Roderick Dashwood laboratory at Oregon State University (subsequently at Texas A&M) demonstrated a second, mechanistically distinct anti-cancer activity: histone deacetylase (HDAC) inhibition. This is an epigenetic mechanism that re-activates silenced tumor suppressor genes by preventing histone deacetylation around their promoters, leaving the chromatin in a permissively transcribed state.

The Myzak 2007 paper (Experimental Biology and Medicine, PMID 17259330) showed that sulforaphane administered orally to humans (a single 68 g serving of broccoli sprouts) inhibited HDAC activity in peripheral blood mononuclear cells, demonstrating that the mechanism is achievable at dietary doses. The active species responsible for HDAC inhibition is not sulforaphane itself but its glutathione conjugate metabolite (sulforaphane-glutathione) and downstream cysteine conjugate, both of which are formed during phase II metabolism.

The clinical importance of HDAC inhibition is well-established in oncology: several cancer drugs approved by the U.S. Food and Drug Administration (vorinostat for cutaneous T-cell lymphoma, romidepsin, and panobinostat, whose approval was withdrawn in 2022 at the application holder's request) work primarily as HDAC inhibitors. Their molecular effect is the same one that sulforaphane achieves at dietary doses — re-activation of p21 (the cell cycle inhibitor), Bax (pro-apoptotic), and other silenced tumor suppressors in transformed cells. The dietary HDAC inhibition is naturally much milder than the pharmaceutical agents, but it is present, mechanistically real, and contributes to the overall chemopreventive effect.

Back to Table of Contents

Breast Cancer Evidence

Breast cancer was the first solid tumor in which sulforaphane chemoprevention was demonstrated in vivo (Zhang Y et al. 1994, PNAS, PMID 8159717: DMBA-induced mammary tumor prevention in rats). The mechanism is multimodal: phase II conjugation of estrogen metabolites that act as DNA-damaging electrophiles (particularly the 4-hydroxyestrogen quinone-imines); HDAC inhibition reactivating tumor suppressor genes commonly silenced in breast cancer; and direct effects on cancer stem cells (next section).

The Atwell 2015 trial (Cancer Prevention Research, PMID 26511489) measured sulforaphane uptake and biomarker effects in 54 women with abnormal mammograms who were scheduled for breast biopsy, randomized to a glucoraphanin supplement or placebo for 2 to 8 weeks. Sulforaphane metabolites were measured in plasma and urine. Within the supplement group, the Ki-67 proliferation marker and HDAC3 fell in benign tissue, but these changes were not significantly different between the groups after adjustment for multiple comparisons. HDAC activity in blood cells fell significantly (P = 0.04). The authors conclude that supplementation for a few weeks is safe but may not be sufficient to change breast tissue tumor biomarkers.

Population-level epidemiology is supportive but not definitive. A combined analysis of the two Nurses' Health Study cohorts (182,145 women, 10,911 invasive breast cancers) found that greater intake of total fruits and vegetables, especially cruciferous and yellow/orange vegetables, went with lower breast cancer risk (more than 5.5 versus 2.5 or fewer servings a day: hazard ratio 0.89; 95% confidence interval 0.83-0.96). A premenopausal figure of approximately 15% lower relative risk at the highest quintile of cruciferous intake is also quoted for these cohorts; it does not appear in that abstract. Mediterranean and East Asian dietary pattern studies also support an inverse relationship, although confounding by other healthy-diet behaviors makes single-food attribution difficult.

The picture after diagnosis is less clear. In the Pathways Study, 3,656 women followed after a breast cancer diagnosis had fewer recurrences, second cancers and deaths with higher cruciferous intake in age-adjusted models (hazard ratio 0.86 per serving; 95% confidence interval 0.77-0.97), but the link was not significant after full adjustment (hazard ratio 0.91; 95% confidence interval 0.78-1.05).

Back to Table of Contents

Prostate Cancer Evidence (Cipolla Randomized Controlled Trial)

Prostate cancer has produced one of the most informative human randomized controlled trials in the sulforaphane chemoprevention literature: the Cipolla 2015 trial (Cancer Prevention Research, PMID 25968598), a randomized double-blind placebo-controlled study in 78 men with biochemical recurrence of prostate cancer after radical prostatectomy. Subjects received either 60 mg a day of a stabilized free sulforaphane or placebo for 6 months, followed by 2 months without treatment.

The trial was designed around the slope of the rise in prostate-specific antigen (PSA), a blood marker, and its primary endpoint was not reached. On secondary measures it reported:

This trial is a human test of sulforaphane in prostate cancer, and its results are in prostate-specific antigen, a biomarker, not in clinical outcomes such as progression or survival. After treatment stopped, the slopes in the two groups were the same. The authors conclude that the treatment "shows promise." The effects on secondary measures were modest, consistent with broccoli's role as an adjunct rather than a primary therapy. The Cipolla trial is also an example of dietary chemoprevention research in patients with measurable disease and surrogate endpoints that respond on a months-to-year timescale.

A second trial tested the food itself. In the 12-month ESCAPE trial, 49 men on active surveillance ate a weekly 300 mL portion of soup made from standard broccoli or from one of two broccoli types bred to deliver 3 and 7 times the glucoraphanin. Biopsies showed that the increase in gene activity in potentially cancer-related pathways seen with standard broccoli was reduced in a dose-dependent way with the richer broccoli. The study was not powered to assess clinical progression.

Mechanism for prostate cancer specifically includes: Nrf2-driven phase II conjugation of androgen-related electrophilic metabolites; HDAC inhibition reactivating prostate-cancer-specific silenced tumor suppressors; growth suppression of human PC-3 prostate cancer cells by 40% in mice, with lower HDAC activity in the tumors (the Myzak xenograft work); direct cytotoxicity to prostate cancer stem cells in cell studies; and modulation of the androgen receptor signaling axis at sustained micromolar concentrations.

Back to Table of Contents

Bladder and Urothelial Cancer

Bladder cancer is one of the few solid tumors where the epidemiologic case for cruciferous vegetable consumption is particularly strong, owing to the unique pharmacology of urinary excretion. Isothiocyanate metabolites (the N-acetylcysteine (NAC) conjugates, also known as mercapturic acids) are concentrated in urine during renal excretion, achieving local concentrations in the bladder lumen substantially higher than in any other tissue. This delivers sustained sulforaphane-equivalent exposure to the urothelium for hours after ingestion.

The Tang 2008 case-control study (Cancer Epidemiology Biomarkers and Prevention, PMID 18398034) reported a 36% lower bladder cancer risk in the highest versus lowest category of raw cruciferous vegetable intake (odds ratio 0.64; 95% confidence interval 0.42-0.97), with no significant association for total cruciferous vegetables, raw consumption showing stronger associations than cooked — consistent with the bioavailability difference between intact-myrosinase raw cruciferous and overcooked vegetables where myrosinase is destroyed. The follow-up Bhattacharya 2010 paper (Carcinogenesis, PMID 19955395) reported that a low oral dose (1 mg/kg) of allyl isothiocyanate (a related compound from mustard seed and horseradish) significantly inhibited the development and muscle invasion of bladder cancers implanted in the bladders of rats, while it was ineffective against the same cancer cells implanted under the skin.

The mechanistic and epidemiologic case combined is mostly discussed for broccoli (and especially broccoli sprouts) as a chemopreventive food in people at elevated bladder cancer risk — current and former smokers, occupational exposure to aromatic amines, and individuals with prior non-muscle-invasive bladder cancer at risk for recurrence. In the Tang study the inverse association with raw crucifers remained significant among current and heavy smokers. On ClinicalTrials.gov, a phase II sulforaphane trial in bladder cancer was withdrawn before starting (NCT03517995), a broccoli sprout extract trial was terminated for low accrual (NCT01108003), and two cruciferous vegetable diet studies in non-muscle-invasive bladder cancer are open or active (NCT06733363, NCT07391137). None of these titles names disease that no longer responds to bacillus Calmette-Guérin (BCG), the standard bladder immunotherapy.

Back to Table of Contents

Colorectal Cancer

Colorectal cancer evidence for sulforaphane has progressed slowly because the gut lumen presents a particular bioavailability challenge: the intact mature broccoli's glucoraphanin can pass through the small intestine and reach the colon, where its hydrolysis depends on the gut microbiome's bacterial myrosinase activity, which varies substantially across individuals. Subjects with low bacterial myrosinase activity get less colonic sulforaphane exposure than those with high activity, blunting the chemopreventive effect.

Despite this, mechanistic studies in colon cancer cell lines and animal models consistently show favorable effects: Nrf2-driven detoxification, HDAC inhibition with reactivation of p21 and other tumor suppressors, induction of apoptosis in transformed colonocytes (with relative sparing of normal colonocytes), and suppression of NF-kB-driven inflammatory signaling that drives the colitis-cancer sequence in inflammatory bowel disease.

Epidemiologic data are supportive but inconsistent. Some pooled cohort analyses show modest inverse associations between cruciferous vegetable intake and colorectal cancer risk; others are null. A 2025 meta-analysis of 17 studies (7 cohort and 10 case-control, 97,595 patients) linked higher cruciferous intake with lower colon cancer risk (odds ratio 0.8; 95% confidence interval 0.72-0.90); its authors caution about differences in study design and dietary assessment, and possible residual confounding. A GSTM1 genotype interaction is also proposed: subjects with the GSTM1-null genotype, who would be predicted to have reduced glutathione conjugation efficiency, are said to benefit more from cruciferous vegetable intake — possibly because the unconjugated isothiocyanate has a longer residence time and more opportunity to engage Keap1 in the colonocyte. The genotype findings are not uniform: in a prostate cancer case-control study on this page's list, men with the GSTM1-present genotype and high broccoli intake had the greatest reduction in risk (odds ratio 0.49; 95% confidence interval 0.27-0.89).

For inflammatory bowel disease patients at elevated colorectal cancer risk from chronic mucosal inflammation, broccoli sprouts have been evaluated in small pilot studies with favorable safety and biomarker results. See Inflammatory Bowel Disease.

Back to Table of Contents

Lung Cancer Chemoprevention

Lung cancer is the leading cause of cancer death worldwide and the obvious target for any chemopreventive food given the well-defined population of high-risk smokers. The relevant mechanisms for broccoli/sulforaphane in lung cancer include the same Nrf2-driven phase II conjugation that accelerated benzene mercapturate excretion in the Qidong trials, plus direct effects on the airway epithelium where many lung cancers originate.

The Hecht laboratory at the University of Minnesota has produced the most thorough mechanistic work, demonstrating that isothiocyanates (sulforaphane plus the related 2-phenethyl isothiocyanate (PEITC) from watercress) prevent NNK (nicotine-derived nitrosamine ketone, the major tobacco carcinogen) induced lung tumors in rodent models by inducing phase II conjugation of NNK's reactive intermediates and by directly inhibiting cytochrome P450 2A6, the enzyme that activates NNK to its carcinogenic form.

Human chemoprevention trials in lung cancer have been less clear-cut. The largest trial of cruciferous-derived isothiocyanates for lung cancer prevention — the 2-phenethyl isothiocyanate trial in 82 smokers with Hecht as senior author (Yuan 2016) — was a 1-week crossover that reduced the ratio showing metabolic activation of NNK by 7.7% (P = 0.023), a change in how the carcinogen is processed, but the trial was not large enough or long enough to assess cancer outcomes.

A longer trial looked at the airway directly. In a randomized phase II trial published in 2025, 43 former smokers took sulforaphane (a potential daily dose of 95 µmol) or placebo for 12 months, and 37 completed it. Bronchial tissue changes did not differ significantly, but the Ki-67 cell-growth marker in biopsies fell 20% with sulforaphane and rose 65% with placebo (P = 0.014). Ki-67 is a possible stand-in for risk, not a measure of lung cancer itself.

For current smokers, smoking cessation is by far the most important known factor; for former smokers and those with continued environmental exposure to combustion pollutants, cruciferous vegetable consumption is discussed as a modest adjunctive measure.

Back to Table of Contents

Effects on Cancer Stem Cells

Perhaps the most interesting and most recent direction in sulforaphane oncology research concerns its effect on cancer stem cells — the rare self-renewing subpopulation within solid tumors that drives long-term tumor growth and metastatic recurrence after conventional treatment. Cancer stem cells are typically more resistant to chemotherapy and radiation than the bulk tumor population, which is one of the reasons that "complete response" by imaging often precedes eventual recurrence.

Several laboratories have demonstrated that sulforaphane preferentially depletes cancer stem cell populations in vitro, including breast cancer stem cells (the CD44+/CD24- subpopulation), pancreatic cancer stem cells (the ALDH+ subpopulation), and prostate cancer stem cells. The mechanism appears to involve disruption of cancer stem cell self-renewal signaling pathways (NF-kB, Sonic hedgehog, Wnt/beta-catenin) and induction of differentiation in the stem cell subpopulation.

Clinical translation is in early stages. The most provocative human data come from pancreatic cancer, where a group in Heidelberg, Germany ran the POUDER pilot study of pulverized broccoli sprout capsules alongside palliative chemotherapy in 40 patients with advanced pancreatic cancer (Lozanovski 2020; unblinded; 29 on sprouts, 11 on placebo). The mean death rate was lower on sprouts in the first 6 months (day 180: 25% versus 43%), but the result was not statistically significant (p = 0.291). Drop-out was high (72% and 55%), and the sprouts sometimes increased digestive problems, nausea and vomiting. Improved tolerability and modest survival benefits are also reported for broccoli sprout extract as an adjunct to chemotherapy. These remain preliminary observations rather than definitive evidence.

Back to Table of Contents

What Broccoli Does Not Do

Honest framing of the chemoprevention evidence requires noting several things broccoli does not do, despite occasional overstated marketing claims:

The realistic framing: broccoli (especially sprouts) is one of the most evidence-supported dietary interventions for primary cancer prevention, with documented mechanism, replicated human biomarker effects, and modest positive clinical trials. It is discussed as an addition to primary prevention, as an adjunct in active surveillance and biochemical-recurrence populations, and as a modest complementary supportive measure during active cancer treatment. It is not a cancer cure.

Back to Table of Contents

Key Research Papers

  1. Zhang Y, Talalay P, Cho CG, Posner GH (1992). A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. PNAS. — PubMed PMID: 1549603
  2. Fahey JW, Zhang Y, Talalay P (1997). Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. PNAS. — PubMed PMID: 9294217
  3. Cipolla BG et al. (2015). Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. Cancer Prev Res. — PubMed PMID: 25968598
  4. Kensler TW et al. (2005). Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts in Qidong, China. Cancer Epidemiol Biomarkers Prev. — PubMed PMID: 16284385
  5. Egner PA et al. (2014). Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China. Cancer Prev Res. — PubMed PMID: 24913818
  6. Myzak MC et al. (2007). Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med. — PubMed PMID: 17259330
  7. Tang L et al. (2008). Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev. — PubMed PMID: 18398034
  8. Atwell LL et al. (2015). Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy. Cancer Prev Res. — PubMed PMID: 26511489
  9. Higdon JV et al. (2007). Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. — PubMed PMID: 17317210
  10. Verhoeven DT et al. (1996). Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers Prev. — PubMed PMID: 8877066
  11. Hecht SS (2000). Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev. — PubMed PMID: 11139137
  12. Joseph MA et al. (2004). Cruciferous vegetables, genetic polymorphisms in GSTM1 and GSTT1, and prostate cancer risk. Nutr Cancer. — PubMed PMID: 15623468
  13. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P (1994). Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. PNAS. — PubMed PMID: 8159717
  14. Bhattacharya A, Tang L, Li Y, Geng F, Paonessa JD, Chen SC, Wong MK, Zhang Y (2010). Inhibition of bladder cancer development by allyl isothiocyanate. Carcinogenesis. — PubMed PMID: 19955395
  15. Yuan JM et al. (2016). Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. Cancer Prev Res. — PubMed PMID: 26951845
  16. Yuan JM et al. (2025). Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer. Cancer Prev Res. — PubMed PMID: 40041932
  17. Lozanovski VJ, Polychronidis G, Gross W, Gharabaghi N, Mehrabi A, Hackert T, Schemmer P, Herr I (2020). Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study. Invest New Drugs. — PubMed PMID: 31250356
  18. Traka MH et al. (2019). Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention-results from the Effect of Sulforaphane on prostate CAncer PrEvention (ESCAPE) randomized controlled trial. Am J Clin Nutr. — PubMed PMID: 30982861
  19. Lai B, Li Z, Li J (2025). Cruciferous vegetables intake and risk of colon cancer: a dose-response meta-analysis. BMC Gastroenterol. — PubMed PMID: 40790161
  20. Tang L et al. (2025). Associations of Cruciferous Vegetable Intake with Breast Cancer Survival in a Diverse Population in the Pathways Study. Cancer Epidemiol Biomarkers Prev. — PubMed PMID: 40298917
  21. Farvid MS, Chen WY, Rosner BA, Tamimi RM, Willett WC, Eliassen AH (2019). Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up. Int J Cancer. — PubMed PMID: 29978479

PubMed Topic Searches

  1. PubMed: Sulforaphane cancer chemoprevention
  2. PubMed: Broccoli sprout RCTs in cancer
  3. PubMed: Cruciferous cancer epidemiology
  4. PubMed: Sulforaphane HDAC inhibition
  5. PubMed: Sulforaphane and cancer stem cells

Back to Table of Contents

Connections

Back to Table of Contents